These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25115234)

  • 1. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.
    Nguyen NC; Anigati EM; Desai NB; Öz OK
    Semin Nucl Med; 2024 Jul; 54(4):488-496. PubMed ID: 38772827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
    Choi H; Cho SW; Kim HH; Yi KH; Park DJ; Park YJ
    Cancer; 2024 Jun; 130(12):2215-2223. PubMed ID: 38376914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
    Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
    Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
    Patel SS; Goldfarb M
    J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
    Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
    Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
    Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
    Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
    Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
    Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma.
    Lang BH; Lo CY; Wong IO; Cowling BJ
    Surgery; 2010 Dec; 148(6):1191-6; discussion 1196-7. PubMed ID: 21134551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
    Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
    Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
    Verkooijen RB; Smit JW; Romijn JA; Stokkel MP
    Eur J Endocrinol; 2006 Dec; 155(6):801-6. PubMed ID: 17132748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
    Sacks W; Wong RM; Bresee C; Braunstein GD
    Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
    Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
    J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.